- Views 84
By discovering a trick the hepatitis C virus uses to evade the immune system, scientists have identified a new antiviral defence system that could be used to treat many virus infections, according to new research published today in eLife.
Viruses have many strategies to avoid immune system defenses. They often do this by hijacking the immune system’s own proteins. One immune protein that is frequently targeted by viruses, including HIV, hepatitis C, and the SARS coronavirus, is called cyclophilin A (CypA). Understanding how CypA is used by viruses could help scientists develop drugs that work against all of them, including the SARS-CoV-2 virus causing the COVID-19 pandemic.
“Previously, clinical trials have shown that blocking CypA reduces the ability of the hepatitis C virus to replicate and boosts the immune response,” explains lead author Che Colpitts, Assistant Professor of Biomedical and Molecular Sciences at Queen’s University, Kingston, Canada. “We set out to understand how CypA helps hepatitis C evade the immune system.”
In the experiments, the team used hepatitis C-infected human liver cancer cells with and without a functioning innate immune system. The innate immune system scans the body for potential threats such as viruses or bacteria and triggers a response. The scientists used a tool called a short hairpin RNA to selectively silence CypA and found that this stopped the virus from replicating only in the liver cells with a functioning innate immune system. They also showed that drugs called cyclophilin inhibitors help block the virus from co-opting CypA and prevent it from multiplying.
CypA is known to attach to an immune protein called protein kinase R (PKR), affecting its ability to detect viruses. So, the team used a gene-editing tool called CRISPR/Cas9 to cut out the gene for PKR in human liver cells with a working innate immune system. In cells without PKR, the cyclophilin inhibitors were less able to stop the virus from reproducing. This happened because PKR was not there to identify the virus and trigger antiviral defenses.
“These findings reveal a new antiviral defence mechanism that suppresses virus growth,” says senior author Greg Towers, Professor of Molecular Virology at University College London, UK. “This opens the door for the development of CypA-targeting antiviral drugs that can be used against many currently untreatable viruses.”
eLife is a non-profit organisation created by funders and led by researchers. Our mission is to accelerate discovery by operating a platform for research communication that encourages and recognises the most responsible behaviours. We work across three major areas: publishing, technology and research culture. We aim to publish work of the highest standards and importance in all areas of biology and medicine, including Immunology and Inflammation, and Microbiology and Infectious Disease, while exploring creative new ways to improve how research is assessed and published. We also invest in open-source technology innovation to modernise the infrastructure for science publishing and improve online tools for sharing, using and interacting with new results. eLife receives financial support and strategic guidance from the Howard Hughes Medical Institute, the Knut and Alice Wallenberg Foundation, the Max Planck Society and Wellcome. Learn more at https://elifesciences.org/about.
To read the latest Immunology and Inflammation research published in eLife, visit https://elifesciences.org/subjects/immunology-inflammation.
And for the latest in Microbiology and Infectious Disease, see https://elifesciences.org/subjects/microbiology-infectious-disease.